The effect of cognitive behavioural therapy for insomnia on sedative-hypnotic use: A narrative review.
Benzodiazepine
Cognitive behavioural therapy for insomnia
General practice
Insomnia
Medication withdrawal
Pharmacotherapy
Primary care
Sedative-hypnotic
Sleeping aid
Sleeping pill
Journal
Sleep medicine reviews
ISSN: 1532-2955
Titre abrégé: Sleep Med Rev
Pays: England
ID NLM: 9804678
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
28
04
2020
revised:
12
07
2020
accepted:
26
07
2020
pubmed:
29
12
2020
medline:
23
11
2021
entrez:
28
12
2020
Statut:
ppublish
Résumé
Although cognitive behavioural therapy for insomnia (CBTi) is the recommended 'first-line' treatment for insomnia, most patients are initially treated with sedative-hypnotic medications. Given the risk of impaired cognitive and psychomotor performance, serious adverse events, and long-term dependence associated with sedative-hypnotics, guidelines recommend that prescriptions should be limited to short-term use and that patients are provided with support for withdrawal where possible. CBTi is an effective insomnia treatment in the presence of sedative-hypnotic use. Furthermore, guidelines recommended that CBTi techniques are utilised to facilitate withdrawal from sedative-hypnotics. However, there is very little research evaluating the effect of CBTi on reduced medication use. The current narrative review integrates 95 studies including over 10,000 participants, investigating the effect of CBTi on reduced sedative-hypnotic use in different populations (e.g., hypnotic-dependent patients, older adults, military personnel), settings (e.g., primary care settings, psychiatric inpatients), CBTi modalities (e.g., self-administered reading/audio materials, digital, and therapist-administered), and in combination with gradual dose reduction programs. Based on this research, we discuss the theoretical mechanistic effects of CBTi in facilitating reduced sedative-hypnotic use, provide clear recommendations for future research, and offer pragmatic clinical suggestions to increase access to CBTi to reduce dependence on sedative-hypnotics as the 'default' treatment for insomnia.
Identifiants
pubmed: 33370637
pii: S1087-0792(20)30147-7
doi: 10.1016/j.smrv.2020.101404
pii:
doi:
Substances chimiques
Hypnotics and Sedatives
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101404Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.